P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results

Authors
Publication date
1 April 2020
Publisher
Elsevier BV
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1016%2Fj.clinph.20...
      Last time updated on 09/03/2025